Severe immune-related adverse events (irAEs) occur in up to 60% of patients with
melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether …

Immune checkpoint blockade (ICB) of PD-1 and CTLA-4 to treat metastatic melanoma (MM)
has variable therapeutic benefit. To explore this in peripheral samples, we characterized …

Abstract Treatment with immune checkpoint blockade (ICB) frequently triggers immune-
related adverse events (irAEs), causing considerable morbidity. In 214 patients receiving …

Despite initial responses,–, most melanoma patients develop resistance to immune
checkpoint blockade (ICB). To understand the evolution of resistance, we studied 37 tumor …

Background Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination)
enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer …

Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but
predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study …

Monoclonal antibodies directed against cytotoxic T lymphocyte–associated antigen-4 (CTLA-
4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic …

The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …

Modulation of the immune system can produce anti-tumor responses in various cancer
types, including melanoma. Recently, immune checkpoint inhibitors (ICI), in single agent …

Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …